SOMA Research

CJC-1295 and Ipamorelin: A Research Guide to the Blend

CJC-1295 with ipamorelin is a blend of two peptides that are routinely paired in research because they act on different receptors to influence the same pituitary cell population. Neither is a variant of the other. Understanding why they are combined — and what a blend does to the analytics on a Certificate of Analysis — is most of what a researcher needs before using one.

SOMA Research supplies this blend for laboratory research use only. It is not a drug, supplement, food or cosmetic, is not approved by the FDA for any use, and is not intended for human or veterinary consumption.

Two peptides, two receptors

CJC-1295 Ipamorelin
Class GHRH analogue Growth hormone secretagogue
Receptor GHRH receptor (GHRHR) Ghrelin receptor (GHS-R1a)
Based on GRF(1–29), modified Synthetic pentapeptide, not a natural fragment
Length 29 amino acids 5 amino acids

Both receptors are expressed on the same somatotroph cells, and both are G-protein-coupled, but they are distinct proteins with distinct signalling. That is the stated rationale for the pairing in the literature: two independent inputs to one cell type, which is a different experimental proposition from giving more of a single agonist.

CJC-1295: four deliberate substitutions

CJC-1295 is GRF(1–29) — the first 29 residues of growth hormone-releasing hormone — carrying four amino acid substitutions, each fixing a specific failure mode of the native sequence:

  • Position 2, Ala → D-Ala. Blocks dipeptidyl peptidase-4 cleavage at the N-terminus, the same problem tesamorelin solves with a hexenoyl group. A D-amino acid is simply not recognised by the protease.
  • Position 8, Asn → Gln. Asparagine deamidates on storage; glutamine does so far more slowly. This substitution is a stability fix, not a potency one.
  • Position 15, Gly → Ala. Reported to improve potency.
  • Position 27, Met → Leu. Removes the only methionine, and with it the sulphoxide oxidation pathway that complicates storage of Semax and MOTS-c.

Three of the four are durability engineering. That is unusual and worth noticing: this is a molecule designed as much for shelf life and handling as for receptor behaviour.

DAC and no-DAC are different molecules

This is the single most common point of confusion and the one to check before using a vial. “CJC-1295” in circulation refers to two things:

  • Without DAC, also sold as Modified GRF(1–29) — the tetrasubstituted 29-residue peptide described above, molecular weight approximately 3,367.9 g/mol.
  • With DAC — the same peptide carrying an added Drug Affinity Complex, a maleimidopropionic acid group that forms a covalent bond with a cysteine on serum albumin. That tether changes the circulating half-life by orders of magnitude and adds mass.

The two have different molecular weights, so a molarity calculation done with the wrong one is wrong. Read the lot CoA for the form and mass actually supplied rather than relying on the product name, and when comparing published results check which form the study used — secondary sources frequently do not say.

Ipamorelin: selective by design

  • Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2
  • CAS number: 170851-70-4
  • Molecular weight: approximately 711.9 g/mol
  • Length: 5 amino acids, C-terminally amidated

Ipamorelin is not derived from a natural sequence. It contains two D-amino acids, a C-terminal amide and Aib (2-aminoisobutyric acid), a non-proteinogenic residue that constrains the backbone — the same residue used in tirzepatide. All of it is protease-resistance engineering, which is why a five-residue peptide survives at all.

Its distinguishing feature in the literature is selectivity. Earlier growth hormone secretagogues of the GHRP series were reported to affect cortisol and prolactin alongside their primary action; ipamorelin is characterised as having a cleaner profile in preclinical models. For comparative work that selectivity is the reason to choose it over an older secretagogue.

What a blend does to a Certificate of Analysis

This is the practical part, and it applies to every blend, not just this one.

A single purity percentage is ambiguous. A blend vial contains two different molecules. “99.7% pure” could describe each component separately, or the combined peak area of both against everything else. Those are different claims. A complete CoA for a blend resolves each component and reports them separately.

Ratio is a separate question from purity. Two components can each be highly pure and still be present in the wrong proportion. Purity says what fraction is not an impurity; it says nothing about how much of each intended component is in the vial. The ratio has to be stated or derived, and a blend CoA that reports only purity leaves it open.

Mass spectrometry should show both. Expect two deconvoluted masses — roughly 711.9 for ipamorelin and the CJC-1295 figure for whichever form is supplied. A single mass on a two-component blend is an incomplete report.

Chromatographic separation is not guaranteed. A 5-residue peptide and a 29-residue peptide have very different retention on reversed phase, which here works in your favour — they should separate cleanly. That is not true of every blend, and it is worth confirming the two peaks are actually resolved rather than assumed.

Our Certificate of Analysis guide covers the individual fields, and measured figures for each SOMA lot are published in the CoA library.

Handling and storage

  • Lyophilised powder: -20°C, protected from light.
  • Reconstituted stock: 2–8°C, aliquoted, used within approximately 30 days.
  • A blend cannot be separated after reconstitution by any means available on a normal bench. Both components go into solution together and stay together, so the ratio in the vial is the ratio in every aliquot. If an experiment needs the components independently, they must be sourced independently.
  • Both components are comparatively robust. Neither contains methionine, cysteine or tryptophan, so the oxidation failure modes that dominate storage of some other compounds do not apply here.
  • Avoid freeze-thaw cycling.

The procedure and the concentration arithmetic — which for a blend must be done per component — are in our reconstitution guide.

Research use only

Research-grade CJC-1295 and ipamorelin are supplied for laboratory use by qualified researchers and institutions. They are not manufactured to pharmaceutical standards, have not been approved by the FDA for any use, and must not be used in or on humans or animals. Nothing in this guide is medical advice or a representation that either compound is safe or effective for any purpose.